ХОЛЕСТЕРИНОВАЯ АТЕРОЭМБОЛИЯ КАК ПРИЧИНА НАРУШЕНИЯ РЕПЕРФУЗИИ МИОКАРДА ПРИ ЭНДОВАСКУЛЯРНОМ ВОССТАНОВЛЕНИИ КОРОНАРНОГО КРОВОТОКА (ОБЗОР ЛИТЕРАТУРЫ)

В статье проанализированы данные отечественной и зарубежной литературы, раскрывающие проблему нарушений коронарного кровотока при эндоваскулярных вмешательствах. С современных позиций представлена роль различных факторов риска развития нарушения реперфузии миокарда. Описаны способы клинической и инструментальной диагностики феноменов замедленного и невосстановленного коронарного кровотока. Подчеркнута необходимость индивидуального подхода к применению лекарственных препаратов для купирования  коронарных нарушений. Акцентировано внимание на современных способах инструментальной профилактики холестериновой атероэмболии. Указано на необходимость исключения  рутинной тромбэктомии при чрескожных коронарных вмешательствах. 

1. Ozkok A. Cholesterol-embolization syndrome: current perspectives. Vasc Health Risk Manag. 2019; 15: 209-220. doi: 10.2147/VHRM.S175150

2. Pantea-Roșan L.R., Bungau S.G., Radu A.F., Pantea V.A., Moisi M.I., Vesa C.M., Behl T., Nechifor A.C., Babes E.E., Stoicescu M., Gitea D., Iovanovici D.C., Bustea C. A Narrative Review of the Classical and Modern Diagnostic Methods of the No-Reflow Phenomenon. Diagnostics (Basel). 2022; 12(4): 932. doi: 10.3390/diagnostics12040932

3. Shahri B., Vojdanparast M. Coronary No-reflow Phenomenon: A Review of Therapeutic Pharmacological Agents. Razavi International Journal of Medicine. 2020; 8(1-4): e1002. doi: 10.30483/rijm.2020.254145.1002

4. Герасимов А.М., Терещенко А.С., Меркулов Е.В., Самко А.Н. Феномен невоcстановленного коронарного кровотока (no-reflow) в практике эндоваскулярного хирурга. Вестник рентгенологии и радиологии. 2014; (1): 51-55. doi: 10.20862/0042-4676-2014-0-1-51-55

5. Majno G., Ames A., Chaing J., Wright R.L. No reflow after cerebral ischemia. Lancet. 1967; 290(7515): 569-570. doi: 10.1016/S0140-6736(67)90552-1

6. Халирахманов А.Ф., Газиев Э.А., Шарафеев А.З., Шарафутдинов Б.М. Развитие феномена «no-reflow» после чрескожных коронарных вмешательств: современные аспекты. Диагностическая и интервенционная радиология. 2019; 13(4): 57-66. doi: 10.25512/DIR.2019.13.4.06

7. Shah M., Mohsin M., Satti K.N. Predictors and in-hospital mortality of slow flow/no-reflow after percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Journal of Akhtar Saeed Medical & Dental College. 2023; 5(03): 144-151. doi: 10.51127/JAMDCV5I3OA05

8. Avci E., Yildirim T., Aydin G., Kiris T., Dolapoglu A., Kadi H., Safak O., Bayata S. Combining clinical predictors to better predict for the no-reflow phenomenon. Eur Rev Med Pharmacol Sci. 2018; 22(15): 4987-4994. doi: 10.26355/eurrev_201808_15639

9. Savic L., Mrdovic I., Asanin M., Stankovic S., Lasica R., Krljanac G., Rajic D., Simic D. The Impact of Kidney Function on the Slow-Flow/No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention: Registry Analysis. J Interv Cardiol. 2022; 2022: 5815274. doi: 10.1155/2022/5815274

10. Kai T., Oka S., Hoshino K., Watanabe K., Nakamura J., Abe M., Watanabe A. Renal Dysfunction as a Predictor of Slow-Flow/No-Reflow Phenomenon and Impaired ST Segment Resolution After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction With Initial Thrombolysis in Myocardial Infarction Grade 0. Circ J. 2021; 85(10): 1770-1778. doi: 10.1253/circj.CJ-21-0221

11. Hu X., Yang X., Li X., Li G., Zhou Y., Dong H. Elevated uric acid is related to the no-/slow-reflow phenomenon in STEMI undergoing primary PCI. Eur J Clin Invest. 2022; 52(4): e13719. doi: 10.1111/eci.13719

12. Somuncu M.U., Akgun T., Cakır M.O., Akgul F., Serbest N.G., Karakurt H., Can M., Demir A.R. The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. J Atheroscler Thromb. 2019; 26(11): 970-978. doi: 10.5551/jat.48413

13. Zhang Q., Hu M., Ma S. Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention. J Atheroscler Thromb. 2021; 28(12): 1289-1297. doi: 10.5551/jat.59832

14. Sondergaard F.T., Beske R.P., Frydland M., Moller J.E., Helgestad O.K.L., Jensen L.O., Holmvang L., Goetze J.P., Engstrom T., Hassager C. Soluble ST2 in plasma is associated with post-procedural no-or-slow reflow after primary percutaneous coronary intervention in ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2023; 12(1): 48-52. doi: 10.1093/ehjacc/zuac146

15. Li Y., Liang X., Zhang W., Qiao X., Wang Z. The Clinical and Angiographic Outcomes of Postdilation after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. J Interv Cardiol. 2021; 2021: 6699812. doi: 10.1155/2021/6699812

16. Fajar J.K., Heriansyah T., Rohman M.S. The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis. Indian Heart J. 2018; 70(3): S406-S418. doi: 10.1016/j.ihj.2018.01.032

17. Gupta S., Gupta M.M. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J. 2016; 68(4): 539-51. doi: 10.1016/j.ihj.2016.04.006

18. Abtan J., Wiviott S.D., Sorbets E., Popovic B., Elbez Y., Mehta S.R., Sabatine M.S., Bode C., Pollack C.V., Cohen M., Moccetti T., Laanmets P., Faxon D., Okreglicki A., Ducrocq G., Steg P.G.; TAO investigators. Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. Arch Cardiovasc Dis. 2021; 114(3): 187-196. doi: 10.1016/j.acvd.2020.09.005

19. Agrawal A., Ziccardi M.R., Witzke C., Palacios I., Rangaswami J. Cholesterol embolization syndrome: An under-recognized entity in cardiovascular interventions. J Interv Cardiol. 2018; 31(3): 407-415. doi: 10.1111/joic.12483

20. Alief W., Mukti C.N., Henry S. Cholesterol crystal embolism: Unraveling its impact on atherosclerotic cardiovascular diseases. Journal of Medicine, Surgery, and Public Health. 2024; 3: 100102. DOI: 10.1016/j.glmedi.2024.100102

21. Sinha S.K., Kumar P., Sharma A.K., Razi M., Pandey U., Sachan M., Shukla P., Aggarwal P., Jha M.J., Thakur R., Krishna V. Perforated balloon technique mediated intracoronary delivery of nicorandil to treat coronary no-reflow phenomenon: a novel pharmacological solution to precarious situation. Am J Cardiovasc Dis. 2021; 11(5): 544-554.

22. Allencherril J., Jneid H., Atar D., Alam M., Levine G., Kloner R.A., Birnbaum Y. Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon. Cardiovasc Drugs Ther. 2019; 33(5): 589-597. doi: 10.1007/s10557-019-06901-0

23. Hu X., Wang W., Ye J., Lin Y., Yu B., Zhou L., Zhou Y., Dong H. Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon. Biomed Pharmacother. 2021; 143: 112196. doi: 10.1016/j.biopha.2021.112196

24. De Luca G., Suryapranata H., Stone G.W., Antoniucci D., Tcheng J.E., Neumann F.J., Van de Werf F., Antman E.M., Topol E.J. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005; 293(14): 1759-1765. doi: 10.1001/jama.293.14.1759

25. Petronio A.S., Rovai D., Musumeci G., Baglini R., Nardi C., Limbruno U., Palagi C., Volterrani D., Mariani M. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J. 2003; 24(1): 67-76. doi: 10.1016/s0195-668x(02)00324-1

26. Simoons M.L., GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. The Lancet. 2001; 357(9272): 1915-24. DOI: 10.1016/S0140-6736(00)05060-1

27. Сухинина Т.С., Певзнер Д.В., Мазуров А.В., Власик Т.Н., Соловьёва Н.Г., Кострица Н.С., Шахнович Р.М., Явелов И.С. Роль блокаторов гликопротеина IIb / IIIa рецепторов тромбоцитов при современном лечении больных с острым коронарным синдромом. Кардиология. 2022; 62(4): 64-72. doi: 10.18087/cardio.2022.4.n2020

28. Callichurn K., Simard P., De Marco C., Jamali P., Saada Y., Matteau A., Schampaert E., Mansour S., Hatem R., Potter B.J. A dual-center analysis of conservative versus liberal glycoprotein IIb-IIIa antagonist strategies in the treatment of ST-elevation myocardial infarction. Sci Rep. 2024; 14(1): 15003. doi: 10.1038/s41598-024-64652-x

29. Bocchino P.P., Angelini F., Gallone G., Frea S., De Ferrari G.M. The cardiovascular safety of sodium nitroprusside in acute heart failure. Expert Opin Drug Saf. 2024; 23(6): 663-666. doi: 10.1080/14740338.2024.2348570

30. Berg R., Buhari C. Treating and preventing no reflow in the cardiac catheterization laboratory. Current cardiology reviews. 2012; 8(3): 209-214.

31. Procopio M.C., Lauro R., Nasso C., Carerj S., Squadrito F., Bitto A., Di Bella G., Micari A., Irrera N., Costa F. Role of Adenosine and Purinergic Receptors in Myocardial Infarction: Focus on Different Signal Transduction Pathways. Biomedicines. 2021; 9(2): 204. doi: 10.3390/biomedicines9020204

32. Laborante R., Bianchini E., Restivo A., Ciliberti G., Galli M., Vergallo R., Rodolico D., Zito A., Princi G., Leone A.M., Aurigemma C., Romagnoli E., Montone R.A., Burzotta F., Trani C., Crea F., D'Amario D. Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2023; 9(2): 173-182. doi: 10.1093/ehjcvp/pvac069

33. Grancini L., Diana D., Centola A., Monizzi G., Mastrangelo A., Olivares P., Montorsi P., Alushi B., Bartorelli A.L., Galassi A.R. The SALINE Technique for the Treatment of the No-Reflow Phenomenon during Percutaneous Coronary Intervention in STEMI. J Clin Med. 2023; 12(6): 2405. doi: 10.3390/jcm12062405

34. Egred M., Bagnall A., Spyridopoulos I., Purcell I.F., Das R., Palmer N., Grech E.D., Jain A., Stone G.W., Nijveldt R., McAndrew T., Zaman A. Effect of Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) on infarct size in anterior STEMI: PiCSO in ACS study. Int J Cardiol Heart Vasc. 2020; 28: 100526. doi: 10.1016/j.ijcha.2020.100526

35. Gibson C.M., Ajmi I., von Koenig C.L., Turco M.A., Stone G.W. Pressure-Controlled Intermittent Coronary Sinus Occlusion: A Novel Approach to Improve Microvascular Flow and Reduce Infarct Size in STEMI. Cardiovasc Revasc Med. 2022; 45: 9-14. doi: 10.1016/j.carrev.2022.07.007

36. Texakalidis P., Letsos A., Kokkinidis D.G., Schizas D., Karaolanis G., Giannopoulos S., Giannopoulos S., Economopoulos K.P., Bakoyannis C. Proximal embolic protection versus distal filter protection versus combined protection in carotid artery stenting: A systematic review and meta-analysis. Cardiovasc Revasc Med. 2018; 19(5 Pt A): 545-552. doi: 10.1016/j.carrev.2017.12.010

37. Giannopoulos S., Sagris M., Giannopoulos S., Tzoumas A., Kokkinidis D.G., Texakalidis P., Koutsias G., Volteas P., Jing L., Malgor R.D. Embolic protection devices for carotid artery stenting: A network meta-analysis. Vascular. 2024; 32(2): 447-457. doi: 10.1177/17085381221140616

38. Celik M., Yuksel U.C., Yalcinkaya E., Gokoglan Y., Iyisoy A. Conservative treatment of iatrogenic left main coronary artery dissection: report of two cases. Cardiovasc Diagn Ther. 2013; 3(4): 244-246. doi: 10.3978/j.issn.2223-3652.2013.10.04

39. De Luca L., Sardella G., Davidson C.J., De Persio G., Beraldi M., Tommasone T., Mancone M., Nguyen B.L., Agati L., Gheorghiade M., Fedele F. Impact of intracoronary aspiration thrombectomy during primary angioplasty on left ventricular remodelling in patients with anterior ST elevation myocardial infarction. Heart. 2006; 92(7): 951-957. doi: 10.1136/hrt.2005.074716

40. Satti Z., Omari M., Bawamia B., Cartlidge T., Egred M., Farag M., Alkhalil M. The Use of Thrombectomy during Primary Percutaneous Coronary Intervention: Resurrecting an Old Concept in Contemporary Practice. J Clin Med. 2024; 13(8): 2291. doi: 10.3390/jcm13082291

41. Zhou L., Hu X., Zhang H., Lu H., Lin Y., Wang W., Yu B., Liang W., Zhou Y., Li G., Dong H. Effects of atorvastatin and rosuvastatin on dysfunctional coronary circulation in patients with ST-segment elevation myocardial infarction. J Int Med Res. 2023; 51(6): 3000605231182547. doi: 10.1177/03000605231182547

42. Михайлова З.Д., Климкин П.Ф. Синдром холестериновой атероэмболии: современное состояние проблемы. Архивъ внутренней медицины. 2020; 10(4): 272-280. doi: 10.20514/2226-6704-2020-10-4-272-280